Search results for "biological product"

showing 10 items of 126 documents

Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospe…

2019

Background: Biologics for moderate-to-severe psoriasis are expensive and treatment substitutions may vastly increase cost. Moreover, administration regimens in routine practice may differ from recommended guidelines. Objectives: To evaluate long-term effectiveness, regimen, drug-survival, and efficiency of self-administered biologics in clinical practice. Methods: We performed a 5-year retrospective study in 72 patients (44 ± 14 years old) with moderate-to-severe psoriasis at the University Hospital La Plana (Vila-real, Spain), treated with subcutaneous biologics. We determined the effectiveness (PASI 75 or PASI < 5), and drug-survival using Kaplan-Meier estimates, and analyzed reasons for …

AdultMalemedicine.medical_specialtyIndividualized dosingCost effectivenessefficacySelf AdministrationKaplan-Meier EstimateDermatologyRoutine practiceDrug CostsustekinumabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineChart reviewPsoriasisUstekinumabmedicineHumansPsoriasisbiologicsIntensive care medicinecost-effectivenessRetrospective Studies030203 arthritis & rheumatologyBiological ProductsDrug Substitutionbusiness.industryModerate to severe psoriasisAdalimumabpsoriasisanti-TNFpersistenceMiddle Agedmedicine.diseaseUniversity hospitalSpainFemaleUstekinumabbusinessmedicine.drugJournal of Dermatological Treatment
researchProduct

Sexual Quality of Life in Patients with Axial Spondyloarthritis in the Biologic Treatment Era.

2019

Author's accepted manuscript. This is a pre-copyediting, author-produced PDF of an article accepted for publication in The Journal of Rheumatology following peer review. The definitive publisher-authenticated version Berg, K. H., Rohde, G., Prøven, A., Benestad, E. E. P., Østensen, M. & Haugeberg, G. (2019). Sexual Quality of Life in Patients with Axial Spondyloarthritis in the Biologic Treatment Era. The Journal of Rheumatology, 46(9), 1075-1083 is available online at: https://www.jrheum.org/content/46/9/1075. Objective. To examine the relationship between demographics, disease-related variables, treatment, and sexual quality of life (SQOL) in men and women with axial spondyloarthritis (ax…

AdultMalemedicine.medical_specialtyMultivariate analysisSexual BehaviorImmunologyDiseasePersonal SatisfactionSeverity of Illness IndexBody Mass Index03 medical and health sciences0302 clinical medicineSex FactorsRheumatologyQuality of lifeInternal medicineSurveys and QuestionnairesSpondylarthritisImmunology and AllergyMedicineOutpatient clinicHumans030212 general & internal medicineAxial spondyloarthritisBASDAI030203 arthritis & rheumatologyBiological Productsbusiness.industryMiddle AgedRheumatologyVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Reumatologi: 759Antirheumatic AgentsQuality of LifeFemalebusinessBASFIThe Journal of rheumatology
researchProduct

Increased proportion of comorbidities but no deterioration of sexual quality of life during a 5-year follow-up in patients with axial spondyloarthrit…

2021

Abstract Objective To explore patient perception of sexual quality of life (SQOL), an important category of QOL, in male and female patients with axial SpA (axSpA) after a 5 year follow-up. Methods A broad spectrum of demographic, disease-related, treatment and SQOL data was collected at baseline and at the 5 year follow-up. SQOL was assessed by the SQOL-Female (SQOL-F) questionnaire. For statistical analysis, McNemar’s tests, paired t-tests and multiple regression analyses were applied. Results A total of 245 axSpA patients (168 men and 77 women) from outpatient clinics were examined (mean age 46 years, mean disease duration 11.9 years at baseline). Compared with baseline, the patients had…

AdultMalemedicine.medical_specialtySexual BehaviorDiseaseComorbidityMcNemar's testRheumatologyQuality of lifeInternal medicineSurveys and QuestionnairesSpondylarthritismedicineOutpatient clinicHumansPharmacology (medical)Axial spondyloarthritisAnkylosing spondylitisBiological Productsbusiness.industryEnthesitisMiddle Agedmedicine.diseaseComorbidityAntirheumatic AgentsQuality of LifeFemalemedicine.symptombusinessFollow-Up StudiesRheumatology (Oxford, England)
researchProduct

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study

2017

AIM To report adalimumab (Ada) efficacy on articular-gastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES). METHODS A cohort of 52 patients with ES was evaluated in the departments of gastroenterology and internal medicine. At baseline, all patients underwent assessment by an integrated gastro-rheumatologic evaluation of articular and gastrointestinal activity, as well patient reported outcomes (PROs) of the HRQoL questionnaires. After this integrated evaluation and following a specific working flowchart, the Ada anti-tumor necrosis factor (TNF)-inhibitor was assigned to a cohort of 30 patients and its clinical efficacy was …

AdultMalemedicine.medical_specialtyTime FactorsTumor necrosis factor-inhibitorMultidisciplinary studyObservational StudyInflammatory bowel diseasesInflammatory bowel diseaseWorkflowEnteropathic spondyloarthriti03 medical and health sciences0302 clinical medicineCrohn DiseaseClinimetric assessmentInternal medicineSpondylarthritisTumor necrosis factor-inhibitorsAdalimumabHumansMedicinePatient Reported Outcome MeasuresPatient reported outcomes030203 arthritis & rheumatologyBiological ProductsTumor Necrosis Factor-alphabusiness.industryRemission InductionAdalimumabGastroenterologyInflammatory Bowel DiseasesGeneral MedicineMiddle AgedPatient reported outcomeEnteropathic spondyloarthritisClinimetric assessment; Enteropathic spondyloarthritis; Inflammatory bowel diseases; Multidisciplinary evaluation; Patient reported outcomes; Tumor necrosis factor-inhibitors; GastroenterologyTreatment OutcomeMultidisciplinary evaluationAntirheumatic AgentsCritical PathwaysQuality of LifeColitis UlcerativeFemale030211 gastroenterology & hepatologyObservational studybusinessmedicine.drug
researchProduct

An up to 7-Year Retrospective Analysis of Biologic and Technical Complication With the All-on-4 Concept

2016

The aim of this study was to evaluate retrospectively biologic and technical complications as well as clinical and radiographic outcomes of patients treated with 4 implants according to the All-on-4 protocol and followed up to 7 years of function. Data from 56 consecutive patients presenting complete edentulous jaw, aged 18 years or older, treated between January 2008 and December 2013, were evaluated. The outcomes were implant and prosthetic survival and success rates, any complications, and marginal bone loss (MBL). Two-hundred twenty-four implants were placed in 56 patients. During the entire follow-up, 1 maxillary implant but no prosthesis failed during the healing process. Fourteen pat…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentRadiographyAlveolar Bone LossDentistryProspective data02 engineering and technologyProsthesis03 medical and health sciencesimplant complications0302 clinical medicinetilted implantsAll-on-4 complete edentulism dental implants complete-arch prosthesis tilted implants implant complicationsdental implantsRetrospective analysisHumansJaw EdentulousMedicineDental Restoration FailureProspective StudiesAgedRetrospective StudiesBiological ProductsAll-on-4business.industrycomplete-arch prosthesisSignificant differencecomplete edentulism030206 dentistryMiddle Aged021001 nanoscience & nanotechnologySurgeryTreatment OutcomeAll-on-4FemaleDental Prosthesis Implant-SupportedImplantOral Surgery0210 nano-technologybusinessComplicationFollow-Up StudiesJournal of Oral Implantology
researchProduct

Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion

2021

International audience; Severe asthma often remains uncontrolled despite effective treatments and evidence-based guidelines. A group of global experts in asthma and biologic medications from nine countries considered the most relevant clinical variables to manage severe asthma in adult patients and guide treatment choice. The resulting recommendations address the investigation of biomarker levels (blood eosinophil count along with fractional concentration of exhaled nitric oxide [FeNO]), clinical features (oral corticosteroid [OCS] dependency, specific comorbid disease entities associated with severe type 2 asthma), and safety considerations. Current evidence suggests that biomarkers, inclu…

Adultsevere asthmamedicine.medical_specialty[SDV]Life Sciences [q-bio]Nitric Oxide[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Health caremedicineImmunology and AllergyHumans[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyIntensive care medicineExpert TestimonyAsthmaBiological Productsalgorithmbusiness.industrymedicine.diseaseAsthma3. Good healthClinical trialClinical research030228 respiratory systemExhalation030220 oncology & carcinogenesisExhaled nitric oxide[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractBiomarker (medicine)Sputumeosinophilsmedicine.symptombusiness[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology
researchProduct

X-ray analysis on the nanogram to microgram scale using porous complexes

2012

X-ray single-crystal diffraction (SCD) analysis has the intrinsic limitation that the target molecules must be obtained as single crystals. Here we report a protocol for SCD analysis that does not require the crystallization of the sample. In our method, tiny crystals of porous complexes are soaked in a solution of the target, such that the complexes can absorb the target molecules. Crystallographic analysis clearly determines the absorbed guest structures along with the host frameworks. Because the SCD analysis is carried out on only one tiny crystal of the complex, the required sample mass is of the nanogram–microgram order. We demonstrate that as little as about 80 nanograms of a sample …

Analytical chemistryCrystallography X-RayMass spectrometryHigh-performance liquid chromatographyAbsorptionlaw.inventionCrystallawAnimalsNanotechnologyMoleculeCrystallizationta116Biological ProductsMultidisciplinaryChemistryMicrochemistryAnalytic Sample Preparation MethodsPoriferaCharacterization (materials science)AlkynesFatty AlcoholsAbsorption (chemistry)CrystallizationPorous mediumPorosityNature
researchProduct

Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.

2011

Cancer remains one of the major causes of death worldwide. The switch to pathological angiogenesis is a key process in the promotion of cancer and consequently provides several new and promising targets to anticancer therapy. Thus, antagonizing angiogenesis cuts off the tumor's oxygen and nutrition supply. This review focuses on angiogenesis inhibitors as option for cancer treatment. Modes of action, adverse effects, mechanisms of resistance as well as new developments are highlighted. One approach in angiogenesis inhibition is intermitting the further VEGF (vascular endothelial growth factor) signal pathway with monoclonal antibodies. Bevacizumab is a highly specific recombinant humanized …

Angiogenesismedicine.drug_classGenisteinAngiogenesis InhibitorsAntineoplastic AgentsBiologyPharmacologyMonoclonal antibodyBiochemistryReceptor tyrosine kinaseNeovascularizationSmall Molecule Librarieschemistry.chemical_compoundGrowth factor receptorNeoplasmsDrug DiscoverymedicineAnimalsHumansPharmacologyBiological ProductsNeovascularization PathologicVascular Endothelial Growth FactorsOrganic ChemistryCancerAntibodies Monoclonalmedicine.diseaseAntineoplastic Agents PhytogenicVascular endothelial growth factorchemistrybiology.proteinMolecular Medicinemedicine.symptomCurrent medicinal chemistry
researchProduct

Chemical Constituents and Pharmacological Properties ofPoria cocos

2011

Poria cocos (Polyporaceae) is a saprophytic fungus that grows in diverse species of Pinus. Its sclerotium, called fu-ling or hoelen, is used in traditional Chinese and Japanese medicine for its diuretic, sedative, and tonic effects. Various studies of this fungus have demonstrated its marked anti-inflammatory activity in different experimental models of acute and chronic inflammation. It is widely used as a constituent of many preparations in Asian medicine, but the number of research papers on its clinical properties is insufficient for establishing its efficacy and safety from a scientific point of view. In this review, we have compiled all the published data concerning the chemistry, pha…

Anti-Inflammatory AgentsPharmaceutical ScienceAntineoplastic AgentsInflammationBiologyPharmacognosyAnalytical ChemistryImmune systemJapanPolysaccharidesPsoriasisDrug DiscoverymedicineHumansImmunologic FactorsSecretionMedicine Chinese TraditionalPolyporaceaePharmacologyBiological ProductsTraditional medicineOrganic ChemistryPoriamedicine.diseasebiology.organism_classificationTriterpenesPolyporusComplementary and alternative medicinePhytochemicalMolecular Medicinemedicine.symptomPlanta Medica
researchProduct

Xenopus Oocyte’s Conductance for Bioactive Compounds Screening and Characterization

2019

Background: Astaxanthin (ATX) is a lipophilic compound found in many marine organisms. Studies have shown that ATX has many strong biological properties, including antioxidant, antiviral, anticancer, cardiovascular, anti-inflammatory, neuro-protective and anti-diabetic activities. However, no research has elucidated the effect of ATX on ionic channels. ATX can be extracted from shrimp by-products. Our work aims to characterize ATX cell targets to lend value to marine by-products. Methods: We used the Xenopus oocytes cell model to characterize the pharmacological target of ATX among endogenous Xenopus oocytes&rsquo

AntioxidantSodiummedicine.medical_treatmentXenopuschemistry.chemical_elementEndogeny+Sodium ChannelsCatalysisArticleAmilorideInorganic Chemistrylcsh:ChemistryXenopus laevischemistry.chemical_compoundXenopus oocyte INaAstaxanthinDrug DiscoverymedicineAnimalsPhysical and Theoretical ChemistryMolecular BiologyIC50lcsh:QH301-705.5SpectroscopyXenopus oocyte INa+Biological Productsbioactive compoundsbiologySodium channelOrganic Chemistry<i>Xenopus</i> oocyte INa<sup>+</sup>marine natural productsGeneral Medicinebiology.organism_classificationElectrophysiological PhenomenaComputer Science ApplicationsShrimpastaxanthinchemistryBiochemistrylcsh:Biology (General)lcsh:QD1-999OocytesInternational Journal of Molecular Sciences
researchProduct